A subline of the human B cell lymphoma DHL-4, grown in the artificial serum-free medium HB101, displayed a resistant phenotype to the activity of an antisense oligodeoxynucleotide (aODN) effective on the parental DHL-4 line. It was found that the cellular uptake of the 18mer aODN in the two cell lines was almost the same. In contrast, the unresponsive subline DHL-4r degraded the aODN very efficiently, in contrast to the stability of aODN inside cells of the parental DHL-4 line. Activation of the degrading 'machinery' combined with selective properties of the artificial medium may be responsible for the loss of responsiveness to aODN.

Oligonucleotide degradation contributes to resistance to antisense compounds / A. Ryte, S. Morelli, M. Mazzei, A. Alama, P. Franco, G. Canti, A.N. Nicolin. - In: ANTI-CANCER DRUGS. - ISSN 0959-4973. - 4:2(1993 Apr), pp. 197-200.

Oligonucleotide degradation contributes to resistance to antisense compounds

P. Franco;G. Canti
Penultimo
;
A.N. Nicolin
Ultimo
1993

Abstract

A subline of the human B cell lymphoma DHL-4, grown in the artificial serum-free medium HB101, displayed a resistant phenotype to the activity of an antisense oligodeoxynucleotide (aODN) effective on the parental DHL-4 line. It was found that the cellular uptake of the 18mer aODN in the two cell lines was almost the same. In contrast, the unresponsive subline DHL-4r degraded the aODN very efficiently, in contrast to the stability of aODN inside cells of the parental DHL-4 line. Activation of the degrading 'machinery' combined with selective properties of the artificial medium may be responsible for the loss of responsiveness to aODN.
English
antisense oligodeoxynucleotides; cellular uptake; resistant cells; stability
Settore BIO/14 - Farmacologia
Articolo
Esperti anonimi
apr-1993
4
2
197
200
Pubblicato
Periodico con rilevanza internazionale
Pubmed
info:eu-repo/semantics/article
Oligonucleotide degradation contributes to resistance to antisense compounds / A. Ryte, S. Morelli, M. Mazzei, A. Alama, P. Franco, G. Canti, A.N. Nicolin. - In: ANTI-CANCER DRUGS. - ISSN 0959-4973. - 4:2(1993 Apr), pp. 197-200.
none
Prodotti della ricerca::01 - Articolo su periodico
7
262
Article (author)
no
A. Ryte, S. Morelli, M. Mazzei, A. Alama, P. Franco, G. Canti, A.N. Nicolin
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/191454
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 10
  • ???jsp.display-item.citation.isi??? ND
  • OpenAlex ND
social impact